Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1985-5-23
|
| pubmed:abstractText |
The atriopeptins are potent relaxants of norepinephrine-constricted aortic strips or are dilators of renal blood vessels in isolated perfused rat kidneys that are constricted by norepinephrine. This vasorelaxant property of the atriopeptins requires the presence of phenylalanine arginine (i.e., atriopeptin II, III, or ser-leu-arg-arg atriopeptin III) residues in the carboxy terminus which are considerably more effective than atriopeptin I (the 21 amino acid peptide which lacks the phe-arg C-terminus) or the core peptide (residues 3-19). However, these artificially in vitro precontracted preparations do not accurately predict the vascular effectiveness of the atriopeptins in intact rats. Intravenous administration of the atriopeptins (including atriopeptin I) to anesthetized rats produces concentration-dependent hypotension, a selective decrease in renal resistance in low doses (determined with microspheres), and pronounced diuresis. At higher doses, atriopeptins increase blood flow in other vascular beds. On the other hand, in the anesthetized dog, injection (intraarterially) of the phe-arg-containing peptides produces a concentration-dependent increase in both renal blood flow and sodium excretion, whereas atriopeptin I is inactive. Although there is a species difference in responsiveness to atriopeptin I, these data demonstrate a direct correlation between the renal vasodilation and diuresis produced by this novel family of atrial peptides.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0009-7330
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
56
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
621-7
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:3156691-Animals,
pubmed-meshheading:3156691-Aorta, Thoracic,
pubmed-meshheading:3156691-Atrial Natriuretic Factor,
pubmed-meshheading:3156691-Blood Pressure,
pubmed-meshheading:3156691-Diuresis,
pubmed-meshheading:3156691-Dogs,
pubmed-meshheading:3156691-Female,
pubmed-meshheading:3156691-Male,
pubmed-meshheading:3156691-Muscle, Smooth, Vascular,
pubmed-meshheading:3156691-Muscle Proteins,
pubmed-meshheading:3156691-Muscle Relaxation,
pubmed-meshheading:3156691-Natriuresis,
pubmed-meshheading:3156691-Perfusion,
pubmed-meshheading:3156691-Rabbits,
pubmed-meshheading:3156691-Rats,
pubmed-meshheading:3156691-Rats, Inbred Strains,
pubmed-meshheading:3156691-Regional Blood Flow,
pubmed-meshheading:3156691-Renal Artery,
pubmed-meshheading:3156691-Vascular Resistance,
pubmed-meshheading:3156691-Vasodilation
|
| pubmed:year |
1985
|
| pubmed:articleTitle |
Comparative vascular pharmacology of the atriopeptins.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro,
Research Support, Non-U.S. Gov't
|